Real World Outcomes and Costs of Osteoporosis Fractures in Ontario, Canada
Client: Amgen Canada Inc.
Project ID: P2017-018 / 2018 0970 103 000
Research Question/Objectives: Osteoporosis and the clinical fractures associated with the disease have significant consequences on human health and quality of life and represent a major burden to society. As with many other chronic and asymptomatic diseases, osteoporosis is under diagnosed and undertreated. The rates of treatment for osteoporosis are also sub-optimal, even among patients who have suffered hip or other fragility fractures. Studies conducted in a variety of different populations indicate that the rates of BMD testing and treatment following fragility fractures are generally <50%, and often <10%. The purpose of this study will be to describe the real-world management (including screening and treatment) and Health Resource Utilization (HRU) of patients subsequent to a primary fragility fracture in Ontario, Canada.
Research Objectives
Primary Objectives:
- To describe the incidence of primary fragility fractures in patients over (65+).
- To describe the real-world management, including screening and treatment, and resource utilization following a primary fragility fracture.
Secondary Objectives:
- To characterize the publicly-insured Ontario fragility fracture patient.
- To describe patient management, including screening and treatment, prior to a fragility fracture in patients (65+).
- To describe the rate of subsequent fractures, related procedures, complications, hospitalizations and mortality subsequent to a primary fragility fracture.
Exploratory Objectives:
- To describe the persistence to osteoporosis treatments in patients (65+) who have had a fragility fracture.
- To describe comorbidities of interest and steroid-use in patients over (65+) who have had a fragility fracture.
- To describe opioid pain medications in patients (65+) prior to, and following a fragility fracture.
- To describe the HRU costs for matched patients who have not had a fragility fracture.
- To describe mortality for matched patients who have not had a fragility fracture.
Results: